Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Efficacy and safety data of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), is not yet well established in the Korean population. We assessed them in ODYSSEY-KT through the pre-specified Korean subanalysis. Methods: In the ODYSSEY-KT study, South Korean and Taiwanese patients with hypercholesterolemia and high cardiovascular risks were randomized (1:1) to alirocumab or placebo. Alirocumab was self-administered subcutaneously at 75 mg every 2 weeks with a maximally tolerated statin dose with or without other lipid- modifying therapies. Alirocumab dose was increased to 150 mg every 2 weeks at week 12 if low density lipoprotein cholesterol (LDL-C) ≥ 70 mg/dL at week 8. Primary endpoint was percent change in LDL-C from baseline to week 24. Results from Korean cohort (n = 83: 40 for alirocumab and 43 for placebo, respectively) analyses are reported here. Results: In alirocumab group, the least square of mean change percent in LDL-C levels was –65.7% (placebo: 11.1%; p < 0.0001) and 92.0% of them achieved LDL-C < 70 mg/dL (placebo: 12.7%; p < 0.0001) at week 24. Alirocumab also showed significantly greater improvements in high density lipoprotein cholesterol (HDL-C), non-HDL-C, total cholesterol, lipoprotein(a), and apolipoprotein B than placebo (p < 0.05). Two consecutive calculated LDL-C values < 25 mg/dL were observed in 37.5% of alirocumab-treated patients. Overall, 45.0% alirocumab-treated and 51.2% placebo-treated patients experienced treatment-emergent adverse events (TEAEs) without discontinuation of treatment due to TEAEs. Conclusions: Alirocumab has demonstrated to be effective in improvement of LDL-C and related lipid profiles in Korean cohort. Alirocumab was generally well tolerated with no significant safety signals.
Abstract
Background/Aims: Efficacy and safety data of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), is not yet well established in the Korean population. We assessed them in ODYSSEY-KT through the pre-specified Korean subanalysis. Methods: In the ODYSSEY-KT study, South Korean and Taiwanese patients with hypercholesterolemia and high cardiovascular risks were randomized (1:1) to alirocumab or placebo. Alirocumab was self-administered subcutaneously at 75 mg every 2 weeks with a maximally tolerated statin dose with or without other lipid- modifying therapies. Alirocumab dose was increased to 150 mg every 2 weeks at week 12 if low density lipoprotein cholesterol (LDL-C) ≥ 70 mg/dL at week 8. Primary endpoint was percent change in LDL-C from baseline to week 24. Results from Korean cohort (n = 83: 40 for alirocumab and 43 for placebo, respectively) analyses are reported here. Results: In alirocumab group, the least square of mean change percent in LDL-C levels was –65.7% (placebo: 11.1%; p < 0.0001) and 92.0% of them achieved LDL-C < 70 mg/dL (placebo: 12.7%; p < 0.0001) at week 24. Alirocumab also showed significantly greater improvements in high density lipoprotein cholesterol (HDL-C), non-HDL-C, total cholesterol, lipoprotein(a), and apolipoprotein B than placebo (p < 0.05). Two consecutive calculated LDL-C values < 25 mg/dL were observed in 37.5% of alirocumab-treated patients. Overall, 45.0% alirocumab-treated and 51.2% placebo-treated patients experienced treatment-emergent adverse events (TEAEs) without discontinuation of treatment due to TEAEs. Conclusions: Alirocumab has demonstrated to be effective in improvement of LDL-C and related lipid profiles in Korean cohort. Alirocumab was generally well tolerated with no significant safety signals.
참고문헌 (28)
- 정지선, "Prevalence and Clinical Characteristics of Dyslipidemia in Koreans", Endocrinology and Metabolism, 32(1), pp.30~35 (2017), 대한내분비학회
- 임달오, "Trends in the Leading Causes of Death in Korea, 1983-2012", Journal of Korean Medical Science, 29(12), pp.1597~1603 (2014), 대한의학회
- "Program for prevention and management of a cardio-cerebrovascular disease" (2017)[URL]
- Lim S, "Increasing prevalence of metabolic syndrome in Korea : the Korean National Health and Nutrition Examination Survey for 1998-2007", Diabetes Care, 34, pp.1323~1328 (2011)
- "Dyslipidemia fact sheet in Korea" (2015)[URL]
- Task Force Members, "ESC", EAS guidelines for the management of dyslipidaemias:the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR), 2016, pp.253, 281~344
- Jacobson TA, "National lipid association recommendations for patient-centered management of dyslipidemia : part 1 : full report", J Clin Lipidol, 9, pp.129~169 (2015)
- Committee for the Korean Guidelines for the Management of Dyslipidemia, "2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)", Korean Circulation Journal, 46(3), pp.275~306 (2016), 대한심장학회[DOI]
- Park JE, "Lipid-lowering treatment in hypercholesterolaemic patients : the CEPHEUS Pan-Asian survey", Eur J Prev Cardiol, 19, pp.781~794 (2012)
- Seidah NG, "New developments in proprotein convertase subtilisin-kexin 9's biology and clinical implications", Curr Opin Lipidol, 27, pp.274~281 (2016)
- Landmesser U, "European Society of Cardiology", European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin, Eur Heart J, pp.2017, 38[DOI]
- Writing Committee, "2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk : a report of the American College of Cardiology task force on clinical expert consensus documents", J Am Coll Cardiol, 68, pp.92~125 (2016)
- Bays H, "Alirocumab as add-on to atorvastatin versus other lipid treatment strategies : ODYSSEY OPTIONS I randomized trial", J Clin Endocrinol Metab, 100, pp.3140~3148 (2015)
- Cannon CP, "Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins : the ODYSSEY COMBO II randomized controlled trial", Eur Heart J, 36, pp.1186~1194 (2015)
- Farnier M, "Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients : the ODYSSEY OPTIONS II randomized trial", Atherosclerosis, 244, pp.138~146 (2016)
- Kastelein JJ, "ODYSSEY FH I and FH II : 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia", Eur Heart J, 36, pp.2996~3003 (2015)
- Kereiakes DJ, "Efficacy and safety of the proprotein convertase subtilisin", kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy : the ODYSSEY COMBO I study, 2015, pp.169, 906~915
- Moriarty PM, "Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm : the ODYSSEY ALTERNATIVE randomized trial", J Clin Lipidol, 9, pp.758~769 (2015)
- Robinson JG, "Efficacy and safety of alirocumab in reducing lipids and cardiovascular events", N Engl J Med, 372, pp.1489~1499 (2015)
- Teramoto T, "Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins : ODYSSEY Japan randomized controlled trial", Circ J, 80, pp.1980~1987 (2016)
- Teramoto T, "Efficacy and safety of alirocumab in Japanese subjects(phase 1 and 2 studies)", Am J Cardiol, 118, pp.56~63 (2016)
- Koh KK, "A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan(ODYSSEY KT)", J Clin Lipidol, 12, pp.162~172 (2018)
- Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease", N Engl J Med, 376, pp.1713~1722 (2017)
- "ACC.18 Joint ACC/JACC late-breaking clinical trials" (2018)[URL]
- Catapano AL, "Efficacy of alirocumab according to background statin type and dose : pooled analysis of 8 ODYSSEY phase 3 clinical trials", Sci Rep, 7, pp.45788~ (2017)
- Dubuc G, "Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia", Arterioscler Thromb Vasc Biol, 24, pp.1454~1459 (2004)
- Kwon JE, "Cholesterol lowering effects of low-dose statins in Korean patients", J Lipid Atheroscler, 3, pp.21~28 (2014)
- 김수경, "Re-Evaluation of Efficacy of Moderate-Intensity Statins in Korean Patients with Type 2 Diabetes Mellitus", Diabetes and Metabolism Journal, 41(1), pp.20~22 (2017), 대한당뇨병학회[DOI]